IRIS analysis finds lower CV, diabetes risk in this subgroup
HONOLULU -- The insulin-sensitizing agent pioglitazone (Actos) appeared effective for secondary prevention in stroke patients with prediabetes, according to a post hoc analysis of the IRIS randomized clinical trial reported here.